Podium to Practice: Data Updates from the 2021 Annual Hematology Meeting That Will Impact the Treatment of Patients with Indolent and Aggressive Lymphomas
Data Updates from the 2021 Annual Hematology Meeting That Will Impact the Treatment of Patients with
Indolent and Aggressive Lymphomas
Release Date: January 24, 2022
Expiration Date: January 23, 2023
Podium to Practice is an accredited continuing education activity featuring two renowned experts who are actively engaged in clinical trials and the management of patients with lymphoma.
This target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with lymphoma.
After participating in this activity, learners should be better able to:
- Evaluate how recently presented data will impact the future care of patients with aggressive lymphoma subtypes, including DLBCL, MCL, PTCL, and Burkitt lymphoma
- Assess the clinical trial results of current and emerging approaches to the treatment of patients with indolent lymphoma subtypes, including FL and MZL
- Develop strategies to integrate novel agents and regimens into practice as they become available in order to improve patient outcomes
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Nebraska Medical Center designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Method of Participation
There are no fees for participating in and receiving continuing education credit for this activity. During the accredited period, participants must: 1) read the educational objectives and conflict of interest disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test, and evaluation will receive an accredited continuing education credit certificate.
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.
The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.
All faculty and planning committee members have no conflicts to disclose with the exception of the following:
Matthew Lunning, DO, FASCO (Moderator)
Division of Oncology and Hematology
Department of Internal Medicine
Fred & Pamela Buffett Cancer Center
University of Nebraska Medical Center
Consultant Fees: AbbVie, Acrotech, ADC Therapeutics, AstraZeneca, Beigene, BMS, Daiichi Sankyo, EUSA, Genentech, InstilBio, Janssen, Karyopharm, Kite, Kyowa Kirin, Legend, Morphosys, Myeloid Therapeutics, Novartis, Spectrum, TG Therapeutics, Verastem
Manali Kamdar, MD
Clinical Director of Lymphoma Services
Division of Hematology, Hematologic Malignancies and Stem Cell Transplantation
University of Colorado Cancer Center
Consultant Fees: AbbVie, Adaptive Biotechnologies, ADC Therapeutics, AstraZeneca, Beigene, Celgene/ Bristol-Myers Squibb, Genentech
Research Support: Genentech, G Therapeutics, Novartis
Speakers Bureau: SeaGen
The following planning committee members have nothing to disclose:
UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Chloe Dunnam; Dru Dace, PhD; Tisheeka Graham-Steed, PhD; Kraig Steubing
Educational grant support provided by Bristol Myers Squibb.
Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.